Gal Markel, MD, PhD, chief scientist and senior oncologist at Sheba Medical Center, discusses the use of fecal microbiota transplant (FMT) for melanoma patients nonresponsive to PD-1 inhibition. FMT patients are reintroduced to PD-1 inhibitors post-transplant. The initial cohort showed 30% of patients achieved objective regression, including two partial responses and one complete response. Dr. Markel indicates further studies are needed to assess variables, such as delivery method and protocols for the eradication of the recipient’s native microbiome.
Learn more by clicking here.